Avalyn Pharma Inc. IPO - What You Need to Know

Thinking about jumping into the Avalyn Pharma IPO? Before you put your hard-earned money on the line, let’s break down what this company is all about in plain English.

Disclaimer: I am an AI, not a financial advisor. IPOs are risky. Always do your own research or talk to a professional before investing.

1. What does this company actually do?

Avalyn Pharma is a clinical-stage biotech company working to treat rare, life-threatening lung diseases, specifically idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis (HP).

Standard treatments today are oral pills that travel through the whole body. This often causes significant stomach issues, leading about 50% of patients to stop taking their medication within a year. Avalyn’s strategy is to turn these proven drugs into an inhaled mist. Using their proprietary eFlow® nebulizer, they deliver medicine directly to the lungs. This approach aims to keep the treatment effective while reducing the side effects that cause patients to quit.

2. How do they make money and are they growing?

Avalyn currently generates no revenue from product sales and has operated at a loss since its inception. They are strictly in the research and development phase, focusing on three main drug candidates:

• AP01 (Inhaled Pirfenidone): Currently being tested in the MIST study for IPF.
• AP02 (Inhaled Nintedanib): Currently being tested in the AURA study for IPF.
• AP03 (Inhaled Nintedanib + Pirfenidone): A combination therapy currently in early development.

The company hopes to disrupt a market for oral therapies that generated over $4 billion in 2024. Their growth depends entirely on proving to the FDA that their inhaled method is safer and easier for patients to use than current pills.

3. What will they do with the money from this IPO?

The company expects to raise approximately $181.8 million. They plan to use these funds to reach key milestones:

• Clinical Trials: The majority of the proceeds will fund the ongoing MIST and AURA studies. They expect to have results by late 2027.
• AP03 Development: This funds the advancement of their combination therapy, with testing planned for late 2026.
• General Operations: This covers ongoing research, manufacturing, and the administrative costs of running the business.

4. Important "Fine Print" for Investors

Avalyn is an "Emerging Growth Company." This allows them to follow simpler accounting rules and provide less detailed financial information than larger, established companies. You will have access to less historical data and public reporting than you might expect from a mature, blue-chip company.

5. The Details: Price and Shares

• The Goal: Offering 11.8 million shares.
• The Price: Expected range of $16.00 to $18.00 per share.
• The Symbol: "AVLN" on the Nasdaq.
• The "Extra" Shares: Underwriters have the option to purchase an additional 1.77 million shares if demand is high.

6. What are the main risks?

• Clinical and Regulatory Risk: If their drug trials fail or the FDA denies approval, the company has no other products to sell. This is a "binary" outcome—the company's value is tied almost entirely to the success of these specific trials.
• Financial Sustainability: Avalyn reported a loss of $85.2 million in 2025. They expect these losses to grow as clinical trials continue. Without more funding or future sales, the company may struggle to stay in business.
• Dependency on Third Parties: Avalyn relies on the eFlow® nebulizer from a partner, PARI Pharma. If that partnership ends or the technology fails, Avalyn cannot deliver its medicine.

Final thought: Biotech IPOs are like high-stakes science projects. Avalyn has a clever strategy to improve patient quality of life, but they are years away from selling a product and generating revenue. Because they are in the early stages, this investment is highly speculative. Only invest what you are comfortable losing!